Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer

1 Mar 2024

Abstract excerpt

PURPOSE It is estimated that the PTEN tumor suppressor gene is functionally lost in 40%-50% of patients with metastatic castration-resistant prostate cancer (mCRPC). There is limited information on the prognostic significance of PTEN status identified with genomic testing. This real-world cohort study assessed PTEN as a genetic biomarker using data from US-based oncology practices. METHODS This retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to PI3K/AKT/mTOR signaling in cancer
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38547419
DOI: 10.1200/po.23.00562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate CancerPMID 38547419Read ↗

Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in EuropeSemantic proximity Read ↗

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learningSemantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.Semantic proximity Read ↗

Differential Response to 177Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

The mutational landscape of lethal castration-resistant prostate cancer.Semantic proximity Read ↗

Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profilesSemantic proximity Read ↗

Transcriptional landscape of PTEN loss in primary prostate cancerSemantic proximity Read ↗

Transcriptional landscape of PTEN loss in primary prostate cancerSemantic proximity Read ↗

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Olaparib for Chinese Metastatic Castration-resistant Prostate Cancer: A Real-World Study of Efficacy and Gene Predictive AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.